Aperio Group’s Karyopharm Therapeutics KPTI Stock Holding History

Aperio Group’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$161K	Sell	695 -127	-15%	-$29.4K	﹤0.01%	2340
2020 Q3	$180K	Sell	822 -36	-4%	-$8.81K	﹤0.01%	2252
2020 Q2	$244K	Sell	858 -48	-5%	-$14.2K	﹤0.01%	2108
2020 Q1	$261K	Buy	906 +186	+26%	+$51.3K	﹤0.01%	1985
2019 Q4	$207K	Buy	+720	New	+$156K	﹤0.01%	2194
2019 Q3	–	Sell	-262	Closed	-$24K	–	2539
2019 Q2	$24K	Buy	+262	New	+$21K	﹤0.01%	2665
2015 Q1	–	Sell	-492	Closed	-$276K	–	1981
2014 Q4	$276K	Sell	492 -869	-64%	-$494K	﹤0.01%	1560
2014 Q3	$714K	Buy	+1,361	New	+$768K	0.01%	984

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DMPV

Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Aperio Group's KPTI Position: Q4 2020 in Review

Aperio Group reduced its Karyopharm Therapeutics (KPTI) stake by 15% in Q4 2020, selling an estimated $29.4K and leaving 695 shares worth $161K. The position accounts for ﹤0.01% of the portfolio, ranked #2340.

Aperio Group first reported a position in KPTI in Q3 2014 and has held it in 8 quarters since. The position peaked at $714K in Q3 2014. 168 funds tracked by Wall St. Rank hold KPTI as of Q4 2020.

Aperio Group held 695 shares of Karyopharm Therapeutics worth $161K as of Q4 2020.
Aperio Group sold 127 Karyopharm Therapeutics shares in Q4 2020, an estimated $29.4K.
Karyopharm Therapeutics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2340 holding.
Aperio Group first reported a position in Karyopharm Therapeutics in Q3 2014 and has held it in 8 quarters since.
Aperio Group's Karyopharm Therapeutics position peaked at $714K in Q3 2014.
168 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.